



AMENDMENTS IN THE CLAIMS

1. (currently amended) A compound of the formula (I)



wherein

~~R₁ and R₂ are, independently of one another,~~

~~1.0 H or~~

~~2.0 a -O-C₁-C₆-alkyl, -O-C₂-C₆-alkenyl, -O-C₂-C₆-alkynyl or -O-C₆-C₁₀-aryl group, in which alkyl, alkenyl and alkynyl are straight chain or branched, and in which the alkyl, alkenyl and alkynyl groups are optionally mono- or disubstituted by:~~

~~2.1 -OH,~~

~~2.2 =O,~~

~~2.3 -O-C₁-C₆-alkyl in which alkyl is straight chain or branched,~~

~~2.4 -O-C₂-C₆-alkenyl in which alkenyl is straight chain or branched,~~

~~2.5 C₆-C₁₀-aryl,~~

~~2.6 NH-C₁-C₆-alkyl in which alkyl is straight chain or branched,~~

~~2.7 NH-C₂-C₆-alkenyl in which alkenyl is straight chain or branched,~~

~~2.8 NH₂ or~~

~~2.9 halogen,~~

~~and in which the aryl groups are optionally mono or disubstituted by substituents 2.1 or 2.3 to 2.9,~~

~~in which the substituents 2.3, 2.4, 2.6 and 2.7 may be further substituted by CN, -amide or oxime functions, and 2.5 may be further substituted by CN or amide functions~~

~~or~~

~~R₁ and R₂ together form a group -O-[(C₁-C₆) alkylene]-O- are -O-CH₂-O-,~~

~~R₃ is~~

~~1.0 H or~~

~~2.0 a C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl or C₆-C₁₀-aryl group, in which alkyl,~~

~~alkenyl and alkynyl are straight chain or branched, and in which the alkyl, alkenyl and alkynyl groups are optionally mono or disubstituted by:~~

~~2.1 OH,~~

~~2.2 =O,~~

~~2.3 O-C₁-C₆-alkyl in which alkyl is straight chain or branched,~~

~~2.4 O-C₂-C₆-alkenyl in which alkenyl is straight chain or branched,~~

~~2.5 C₆-C₁₀-aryl,~~

~~2.6 NH-C₁-C₆-alkyl in which alkyl is straight chain or branched,~~

~~2.7 NH-C₂-C₆-alkenyl in which alkenyl is straight chain or branched,~~

~~2.8 NH₂ or~~

~~2.9 halogen,~~

~~and in which the aryl groups are optionally mono or disubstituted by substituents 2.1 or 2.3 to 2.9,~~

~~in which the substituents 2.3, 2.4, 2.6 and 2.7 may be further substituted by CN, -amide or oxime functions, and 2.5 may be further substituted -CN or amide, and~~

R₄ is

CO₂R₃, CO₂NHR₃, CHO, CH₂OR₃, CH₂OSi(R₃)₃, CH₂Br, CH₂CN, wherein R₃ is as defined above,

1.0 H or

2.0 a C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl or C₆-C₁₀-aryl group, in which alkyl, alkenyl and alkynyl are straight-chain or branched, and in which the alkyl, alkenyl and alkynyl groups are further mono- or disubstituted by:

2.1 -OH,

2.2 =O,

2.3 -O-C₁-C₆-alkyl in which alkyl is straight-chain or branched,

2.4 -O-C₂-C₆-alkenyl in which alkenyl is straight-chain or branched,

2.5 -C₆-C₁₀-aryl,

2.6 -NH-C₁-C₆-alkyl in which alkyl is straight-chain or branched,

2.7 -NH-C₂-C₆-alkenyl in which alkenyl is straight-chain or branched,

2.8 -NH₂ or



2.9 halogen,

and in which the aryl groups are further mono- or disubstituted by substituents 2.1 or 2.3 to 2.9,


in which the substituents 2.3, 2.4, 2.6 and 2.7 are further substituted by -CN, -amide or -oxime functions, and 2.5 are further substituted -CN or amide.

or a stereoisomeric form of the compound of the formula (I) or a physiologically tolerated salt of the compound of the formula (I) or a salt of a stereoisomeric form of the compound of the formula(I).


2. (currently amended) The compound according to claim 1, which is the compound of formula (II)



3. (currently amended) The purified compound according to claim 1, which is the compound of formula (III)




4. (currently amended) The purified compound according to claim 1, which is the compound of formula (IV)



5. (currently amended) A process for the preparation of the compound of formula ~~(I)~~, IV according to claim 4 and each physiological tolerated salt comprising:

1. extracting the plant *Beilschmiedia fulva*, PLA 101037, or cell cultures of the plant *Beilschmiedia fulva*, PLA 101037, under suitable conditions,
2. isolating the compound of the formula (IV),



3. ~~where appropriate derivatizing to a compound of the formula (I) and/or reacting to give a physiologically tolerated salt of the compound of the formula (I)~~
where appropriate reacting to give a physiologically tolerated salt of the compound of the formula (IV).

6. (canceled)

7. (original) A pharmaceutical composition comprising a compound of claim 1 or a pharmacologically tolerable salt thereof and one or more physiologically acceptable excipients.

8. (original) A process for the preparation of a pharmaceutical composition as claimed in claim 7, comprising bringing a compound of formula (I), or a pharmacologically tolerable salt thereof, into a suitable administration form using one or more physiologically suitable excipients.

9.-10. (canceled)

11. (currently amended) A method of treating allergies, asthma and ~~inflammatory symptoms~~ inflammation associated with asthma in a patient comprising administering to a patient in need thereof an effective c-maf and NFAT inhibiting amount of a compound according to claim 1.